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Prostate cancer (PCa) is the most common malignancy and the second most common
cause of cancer death in Western men. Despite its prevalence, PCa has proven very
difficult to propagate in vitro. PCa represents a complex organ-like multicellular structure
maintained by the dynamic interaction of tumoral cells with parenchymal stroma,
endothelial and immune cells, and components of the extracellular matrix (ECM). The
lack of PCa models that recapitulate this intricate system has hampered progress toward
understanding disease progression and lackluster therapeutic responses. Tissue slices,
monolayer cultures and genetically engineered mouse models (GEMM) fail to mimic
the complexities of the PCa microenvironment or reproduce the diverse mechanisms
of therapy resistance. Moreover, patient derived xenografts (PDXs) are expensive, time
consuming, difficult to establish for prostate cancer, lack immune cell-tumor regulation,
and often tumors undergo selective engraftments. Here, we describe an interdisciplinary
approach using primary PCa and tumor initiating cells (TICs), three-dimensional (3D)
tissue engineering, genetic and morphometric profiling, and humanized mice to generate
patient-derived organoids for examining personalized therapeutic responses in vitro and
in mice co-engrafted with a human immune system (HIS), employing adaptive T-cell- and
chimeric antigen receptor- (CAR) immunotherapy. The development of patient specific
therapies targeting the vulnerabilities of cancer, when combined with antiproliferative and
immunotherapy approaches could help to achieve the full transformative power of cancer
precision medicine.
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Although adult organs are three dimensional (3D), our ability to understand tissue development,
function, and cellular patho-physiology has mainly relied on knowledge from flat two-dimensional
(2D) cell culture studies. With more knowledge gained, new approaches have been developed,
for growing both normal and diseased tissues, allowing the creation in a dish of organ-specific
mini 3D structures termed “organoids” (Lancaster and Knoblich, 2014). Organoids have been
generated from both pluripotent stem cells (PSCs) and adult stem cells (SCs) by mimicking
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the cellular and tissue developmental processes (Yin et al., 2016).
These organoids are believed to stem from single multipotent
SCs or organ progenitors capable of differentiation and self-
organization to form structures morphologically and functionally
resembling the corresponding in vivo organ (Cukierman et al.,
2002; Birgersdotter et al., 2005; Griffith and Swartz, 2006; Nelson
and Bissell, 2006). Thus, the 3D organoid model offers a vast
range of attractive employments into the biomedical field.
The knowledge around the capacity of an individual cell to
form a whole organism dates back to the early 1900, with the
discovery of self-organized dissociated sponge cells that are able
to rear an entire multi-cellular animal (Wilson, 1907). Since
then, organoid culture systems have been established with the
aim of supporting SC engineering applications and, lately, for
the utilization in examining personalized therapeutic approaches
and validating targets for cancer therapy (Bissell and Labarge,
2005; Postovit et al., 2007; Hynds and Giangreco, 2013). For the
latter, there is currently a strong need to explore and validate the
utilization of patient derived organoids for the developing science
of precision medicine. To achieve this goal, it is essential to point
out that when it comes to applying precision medicine principles
to the oncology practice, there is a widespread tendency to
underestimate the complexities of cancer as a genetic disease, for
instance assuming that targeting specific genomic vulnerabilities
will correspond with therapy effectiveness. Nevertheless, if
genomic expression profiling helps to narrow down and uncover
a certain number of deregulated gene patterns, whose expression
varies between different cell/patient populations, and drive
aberrant cancer pathways, transcriptional profiling might not
fully correlate with the functional state of the encoded cellular
proteins. Moreover, profiling does not provide information on
protein-protein interactions (Hunter, 2000; Celis and Gromov,
2003), and most critically, nor does it fully account for
the extreme clonal heterogeneity recently revealed (Barbieri
et al., 2013). In this regard, the possibility to functionally
test treatment protocols directly on patient tumor cells, before
therapy implementation, in an “in vivomimicking” environment,
and preferably by utilizing single cell assays (Ryan et al., 2011), or
at a minimum by performing studies at the clonal level (Sabaawy,
2014), would definitely address these limitations. Here, we
present the key strengths, weaknesses, and possible applications
of the 3D organoid models into the biomedical field, with a
particular emphasis on the prostate cancer (PCa) therapeutic
arena.
ORGANOIDS IN PROSTATE CANCER
Advanced and metastatic PCas are common causes of cancer
related death in Western men (Siegel et al., 2015). They are
characterized by a remarkable genomic complexity mirrored
in the clinically variable behavior of the disease (Berger et al.,
2011). In the human body, PCa is sustained within a complex
organ-like structure whose survival and function relies upon the
dynamic interactions of tumor cells with stromal, endothelial,
immune cells and the surrounding extracellular matrix (ECM;
Moore and Lemischka, 2006). Despite its incidence, PCa has
proven very difficult to propagate in vitro and the lack of
preclinical models that reproduce the cellular diversity of the
tumor niche and the interactions with the ECM has hampered
advancements toward interrogating disease progression and
therapeutic responses (Izumchenko et al., 2016). For instance, cell
lines solely grown in monolayers lack patients’ PCa heterogeneity
(Wilding and Bodmer, 2014). Moreover, although multi-allelic
genetically engineered mouse models (GEMM) contribute to the
understanding of different phases of tumorigenesis, they fail to
mimic PCa progression or to reproduce the diverse mechanisms
of therapy resistance (Meads et al., 2009). On the other hand,
patient derived xenografts (PDXs) while more representative
of PCa are difficult to establish, expensive, time consuming,
tumor clones undergo selective engraftments, and lack immune
regulation (Garrido-Laguna et al., 2012; Julien et al., 2012;
Cassidy et al., 2015). The human prostate is characterized by
glandular epithelial/diverse cell organization. When prostatic
tissues are maintained in culture and embedded in a complex
matrix environment, this 3D culture system would more closely
reflect the natural in vivo behavior of PCa tissue, rendering its
in vitro propagation easier and its utilization for prediction of
therapeutic response much more reliable.
HUMAN PROSTATE 3D CULTURE
Ex vivo culture of the human prostate tissues were originated
in the 1970s following the culture of mouse prostate tissues
(Pretlow et al., 1995). A variety of culture methods have since
been developed involving the use of tissue slices and culture
over various scaffolds. These different culture methods have been
shown to allow benign prostatic tissue viability and maintenance
for about a week, although the culture of human PCa tissues
is generally not successful using these approaches (Centenera
et al., 2013). To date, human PCa organoids have only been
generated from patients with advanced disease (Gao et al., 2014).
However, molecular studies have clearly established that the
primary malignancy is the reservoir of resistant clones causing
waves of metastatic seeding to distant sites (Haffner et al., 2013;
Gundem et al., 2015). Indeed, while primary PCa is multifocal
with extensive clonal heterogeneity (Berger et al., 2011; Fontugne
et al., 2016), lethal metastatic disease is mono- (or oligo-)
clonal only acquiring subclonal heterogeneity from adaptations
to the microenvironment and/or from the selective pressure of
therapy (Barbieri et al., 2013), which might mask fundamental
elements of disease progression. Although a 3D organoid system
derived from the later stages of the disease may help progress
toward developing drugs to control secondary lesion growth and
improve the quality of life of patients, identifying the subset of
localized PCa foci that are responsible for tumor progression is
the key to a more widely successful treatments. Thus, envisioning
an efficient culture system to generate single cell-derived PCa
organoids from the localized disease, that mirror patients’
genomic alterations, would allow the production of personalized
biological systems amenable not only to measure treatment
agents activity in real time, but also, more importantly, to identify
those with highest potential for efficacy in the clinic. This suggests
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that the opportunity exists to make dramatic improvements in
life-extending, possibly curative, therapies by focusing on the
assessment of the vulnerabilities of the heterogeneous primary
tumor sites.
GENERATING ORGANOIDS FROM
PATIENT DERIVED CELLS
In vitro 3D epithelial cell cultures have been used to support
growth of mammary epithelium (Stingl et al., 2001), hepatic
(Mitaka et al., 1999), and intestinal villi (Sato et al., 2009).
By utilizing epithelial and mesenchymal developmental signals
in 3D organotypic culture containing ECM, we regenerated
single stem cell-derived benign prostatic hyperplasia (BPH)
and naïve PCa into 3D organoids comprised of both epithelial
and mesenchymal tissues. We first established methods for the
processing of PCa tissues to generate organoids for examining
the genomic vulnerabilities of each patient’s cancer tissues
with targeted therapy under IRB-approved protocols. Briefly,
immediately after the surgical removal of the prostate, the
specimen is retrieved from the operating room, registered
and serially sectioned from apex (slice 1) to base (slice 6;
Figures 1A–C). Tissues obtained from slices 1 and 2 are utilized
for DNA and RNA extraction, respectively, and frozen for
subsequent sequencing, genomic profiling andmolecular studies.
H&E and immunohistochemistry (IHC) sections, from slices
3 and 5, respectively, are examined to identify and select a
number of tumor foci based on the expression of PCa-specific
biomarkers (Bansal et al., 2014). H&E slides are digitally scanned
and images are subjected to foci mapping. Fresh tissues are
obtained from the foci in slices 4 and 6 that correspond to
the mapped tumor areas; cells are isolated and subjected to
organoid formation (Bansal et al., 2014). Prostate organoids are
coded, retrospectively matched with database record of mapped
tumor foci and genomic profiles then examined for therapeutic
responses (Sabaawy et al., 2015).
In proof-of-concept studies, each patient-derived prostate
organoids recreated the cellular phenotypic profile of the parental
cell of origin in the primary PCa tissue. We matched the
normal, prostatic intraepithelial neoplasia (PIN) and PCa foci
with regions of normal glands, PIN and PCa in the patient’s
H&E stained and mapped section (Figures 2A,B) along with
marked organoids for cytokeratins (CKs) and prostatic specific
antigen (PSA). The prostate epithelium is composed of basal cells,
including SCs and transient amplifying (TA) cells, terminally
differentiated luminal cells and rare neuroendocrine cells. These
cells can be distinguished based on the expression of a variety of
markers (Collins and Maitland, 2006). Most basal cells express
CK5/14, p63, CD44, CD49, and do not express CK8/18 or PSA.
Luminal cells express relatively high levels of PSA and CK8/18,
while TA (intermediate) cells co-express basal and luminal
markers (Collins and Maitland, 2006). In contrast, PCa diagnosis
typically relies on lack of expression of basal cell markers (Prins
and Putz, 2008; Bansal et al., 2014). Organoids derived from cells
of mirrorimage tissue showed the expected CK/PSA staining that
distinguishes normal, PIN and PCa (Collins and Maitland, 2006;
Prins and Putz, 2008; Bansal et al., 2014). For instance, PSA−/low
staining in cells that are CK14+ represents organoids from TA
cells. Smaller organoids with a similar number of PSA+ and
CK14+ cells were derived from a normal gland. Organoids with
higher PSA than CK14 represent basal cell derived PIN, while
larger organoids with PSAhi/CK14−/low cells were PCa organoids
(Figure 2C).
In these studies, we first derived organoids from the bulk
of tumor cells and found that only a fraction of these cells
(∼1%) have organoid forming potential. Using 3D chambers
of Matrigel, we have generated prostate organoids that have
survived for 3–6 months and could be re-derived to generate
serial cultures (Bartucci et al., 2015). In one study, we utilized
hypoxic conditions to obtain organoids from 21 out of 24
attempted PCa samples with an efficiency of ∼87% (Bartucci
et al., 2015). Organoids could also be derived from adult tissue
SCs (Shamir and Ewald, 2014) or their tumorigenic counterparts
(Sato et al., 2011) and we documented that the ability to form
clonal single cell-derived prostate organoids was increased in the
CD49bhiCD29hiCD44hi cell subpopulation (TICs) that has stem-
like features and in vivo tumorigenic potentials (Bansal et al.,
2014).
Because organoids can be maintained in culture over time,
they offer a unique opportunity to test multiple agents and their
associated toxicity and selective pressure on tumor cells, thus
avoiding those agents that are ineffective. That said, although
undeniably valuable, there are however still important limitations
alongside studies and applications of in vitro 3Dmodels (Yamada
and Cukierman, 2007). For instance, the absence of a vascular
environment in a petri dish makes it difficult for organoids
to fully grow and mature in a functional tissue/organ/tumor.
Furthermore, in the case of cancer organoids, the lack of diverse
cell-cell interactions such as epithelial-stromal or epithelial-
endothelial or, even more importantly, of an active host immune
response, can still influence the experimental outcomes when
patient’s responses to therapy are considered.
It has been proven that under the appropriate conditions,
endothelial, stromal, and cancer cells can collectively be grown
yielding an organotypic tumoral niche (Chong et al., 2014),
however, this will not resolve the absence of an efficient
immune system. These challenges could be overcome with
innovative approaches where primary PCa cells, co-cultured
three-dimensionally with stromal and endothelial cells, will
subsequently be injected into humanized mice engrafted with the
same patient’s immune cells. As a consequence, personalized and
immune precision therapy approaches can then be examined to
identify the optimum treatment sequences and monitor therapy-
induced clonal selection processes that are frequent causes of
relapse (Baca et al., 2013).
DEVELOPING MICE WITH PROSTATE
ORGANOIDS AND A HUMAN IMMUNE
SYSTEM
While immunotherapy has been successfully integrated into
the treatment strategies for melanomas and blood cancers, the
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results for PCa treatment have been disappointing. To date,
the only FDA-approved anticancer vaccine is Sipuleucel-T. A
Phase III IMPACT (Immunotherapy Prostate AdenoCarcinoma
Treatment) trial that included 512 metastatic castration resistant
PCa patients showed that Sipuleucel-T improved the overall
survival (OS) by ∼4 month and reduced the risk to die by
only 22% (Kantoff et al., 2010). Alternative immune approaches
include utilizing tumor-associated antigens (TAAs) that stimulate
cellular or humoral responses and can efficiently eliminate
tumor cells in some cases (Mittal et al., 2014), since peptides
derived from TAAs can be presented with MHC class I/II
by CD8+/CD4+ T cells, respectively. Adaptive T-cell- and
chimeric antigen receptor- (CAR)-mediated immunotherapy
approaches have shown recent successes, but there are no
FIGURE 1 | An interdisciplinary approach for utilizing patient derived organoids for prostate cancer precision therapy. (A) Patients with localized and
metastatic PCa were enrolled after an informed consent. Patients underwent first line treatment, and then had radical prostatectomy (RP) and biopsy of metastatic
(mets) lesions. Next, Patients’ tissues from RP and mets were used for generating personalized organoids. The prostate gland was examined by an experienced
Pathologist to identify PCa foci, and under aseptic conditions divided into six sections. Sections 1 and 2 are used for DNA and RNA for sequencing to define PCa
subgroups. Sections 3 and 5 are used for PCa foci mapping based on Hematoxylin and eosin (H&E) and IHC staining, and Fluorescent in situ hybridization (FISH) for
the TMPRSS2-ERG fusion. Slides are scanned into digital images, while mirror sections 4 and 6 are isolated under aseptic conditions and cells are separated for
organoid culture. (B) Demonstration of prostate gland sectioning. Inset indicates H&E staining with the tumor area mapped. (C) H&E, IHC, and FISH representative
images from a case used for prostate cancer tissue mapping. The tumor areas were identified based on histological and IHC staining for ERG and AMACR and
positivity for the Ets fusion (TMPRSS2-ERG) by FISH. Images were digitally scanned, stacked, and image segmentation was used for PCa mapping. Organoids from
normal adjacent tissue (NAT), PCa primary foci, and node or bone metastasis were generated for each patient, based on the collective database information, including
tumor foci, vascular density and tumor infiltrating lymphocytes, with computer assisted design (CAD) programs. Genomic profiling of primary, mets and their organoids
is done after exome, whole genome sequencing (WGS), and RNA sequencing. PCa organoid response to therapy when examined in patient derived organoids
allowed the correlation of organoid response to ongoing first line therapy and selecting for second line, more biologically effective therapy, in order to prevent disease
progression and development of therapeutic resistance.
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FIGURE 2 | PCa organoids to model tumor heterogeneity and develop immunotherapy in humanized mice. (A) H&E of RP section from a PCa patient
shown in 4x. (B) The outlined area in (A) is displayed in 200x, showing the outline of benign prostate gland (green), prostatic intraepithelial neoplasia (PIN) region
(yellow), and a three foci region of PCa (Blue). (C) Single-cell organoids reflect the heterogeneity in primary PCa. Immunofluorescence (IF) images show DAPI as
nuclear staining, PSA (center region), CK14 (in cells lacking PSA staining, i.e., transit amplifying cells). Multiple organoids derived from the same patient’s PCa
expressing PSA and CK14 (right), low and localized (top) and low/negative (bottom). (D) Human immune system (HIS) reconstitution in NRG HIS. Fraction of human
CD45+ cells of total CD45+ cells detected in the HSC transplanted NRG mice. (E) Indicated leukocyte subpopulations were determined by FACS analysis of PBMC
in NRG mice. (F) Indicated immune cell subpopulations in NRG and HIS-NRG mice are shown as dot plots.
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platforms to examine these immunotherapy strategies with
standard therapy (Schreiber et al., 2011), or in the context
of precision medicine. Primary PCa cells are difficult to
engraft in conventional immunocompromised mice. We need
to utilize highly immunodeficient mice that will not reject PCa
xenografts, will allow high engraftment rates, and will support
the differentiation and growth of human cells and tissues. This
could be achieved with engineered “Humanized” mice (Drake
et al., 2012). Therefore, the goal of our ongoing studies is
to generate immune humanized mice with implanted prostate
organoids to study PCa tumor-immune cell interactions and
quantify the effects of PCa therapy on immune responses to
tumors as a stepping-stone toward developing patient specific
immunotherapy.
RECONSTITUTION OF MICE WITH A
HUMANIZED IMMUNE SYSTEM
Humanized mice are immunodeficient animals engrafted with
human hematopoietic stem cells (HSCs) that give rise to
various lineages of human blood cells throughout the life of
the mouse (Drake et al., 2012). By simultaneously humanizing
the immune system of recipient animals and challenging them
with implanted human tumor cells in prostate organoids,
the interactions between human immune cells and tumor
cells can be interrogated (Chen and Mellman, 2013). Mice
engrafted with components of a human immune system
(HIS) are routinely generated by engrafting human HSCs
isolated from human fetal liver (HFL), BM, or cord blood
into highly immunodeficient mouse strains, such as NOD
Rag1−/− IL2Rαnull (NRG) mice, NOD SCID IL2Rαnull (NSG)
or Balb/C Rag2−/− IL2Rαnull (BRG), that support better
human hematopoietic cell engraftment (Figures 2D–F). We have
pursued improved strategies to enhance the human immune
cell reconstitution and function in humanized mice (Billerbeck
et al., 2014). A variety of other strategies are also being pursued,
including, but are not limited to: the expression of human
orthologs of non-redundant cytokines with limited biological
cross-reactivity to foster the development of human immune
cell lineages which currently do not develop efficiently in
conventional humanized mice; expression of human MHC in
the absence of mouse MHC to ensure faithful presentation of
self- and virally-derived peptides to human T-cells and to reduce
graft-versus-host-disease; co-transplantation of HSC donor-
matched human thymic cortical epithelium to facilitate proper
T-cell selection; the improvement of lymphoid architectural
organization, especially in the spleen and lymph-nodes, to
allow for adequate T- and B-cell priming; genetic replacement
of non-compatible immune cell receptors and chemokines
expressed on non-hematopoietically derived cells to improve
immune functions such as immune cell trafficking; and the
introduction of a human microbiome to account for the effects
of species-specific commensals on the immune system (reviewed
in Shultz et al., 2012). We are now poised to reconstitute
mice with a HIS from PCa patients along with their prostate
organoids to examine the personalized immune responses against
PCa cells in the presence or absence of PCa therapy to
overcome resistance and provide new approaches for cancer
therapy.
With the exciting potential that these models offer, it is worth
remembering that HIS mice still have remaining challenges.
For example, humanized mice are limited by the availability
of human tissue donors and the species incompatibility of
ligands. They also lack other human cell lineages that could
be potentially involved in cancer progression and metastasis
(e.g., resident hepatocytes, osteocytes, adipocytes, nerve cells,
etc.), and lack absolute efficiency of a memory-based HIS in
mice. In the future, advances in the regenerative medicine field
would allow for utilizing artificial human organoids and/or
cells with multilineage engraftment potentials derived from
tissue-restricted/induced progenitors or induced pluripotent
stem (iPS) cells for generating ideal multicellular “humanized”
models.
One of the important objectives of biomedical sciences is
to decipher the understanding of the fundamental biological
principles in order to improve clinical-pathological outcomes. It
is clear that no single model is likely to recapitulate all aspects of
the complex genetics and biology of human cancers; therefore,
understanding the strength and limitation of each model is
necessary tomaximally leverage these complimentary engineered
model systems to facilitate the development of improved
therapeutic approaches. 3D cultures enable the identification of
cellular interactions and molecular signals capable of promoting
tissue regeneration and disease progression. Primary human
cells or tissues can be used to guide the choice of personalized
interventions, to test therapeutic schemes or to grow replacement
tissues from the cells of a given patient.
The success of this approach will involve the expertise of an
interdisciplinary team of scientists, clinicians, and bioengineers
and require an extraordinary level of standardization;
nevertheless, given the vast applications, we believe that 3D
cultures represent the new frontiers of precision medicine.
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